Home/Filings/4/0000920465-20-000145
4//SEC Filing

Chawla Lakhmir S 4

Accession 0000920465-20-000145

CIK 0000920465other

Filed

Sep 16, 8:00 PM ET

Accepted

Sep 17, 4:57 PM ET

Size

9.0 KB

Accession

0000920465-20-000145

Insider Transaction Report

Form 4
Period: 2020-07-01
Chawla Lakhmir S
Chief Medical Officer
Transactions
  • Award

    Common Stock

    2020-09-15$3.85/sh+286$1,10113,447 total
  • Award

    Employee Stock Option (Right to Buy)

    2020-09-15+286286 total
    Exercise: $4.53Exp: 2030-09-15Common Stock (286 underlying)
  • Award

    Employee Stock Option (Right to Buy)

    2020-07-01+60,00060,000 total
    Exercise: $4.52Exp: 2030-07-01Common Stock (60,000 underlying)
Footnotes (2)
  • [F1]These shares were acquired on 09/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
  • [F2]The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years.

Issuer

LA JOLLA PHARMACEUTICAL CO

CIK 0000920465

Entity typeother

Related Parties

1
  • filerCIK 0001646626

Filing Metadata

Form type
4
Filed
Sep 16, 8:00 PM ET
Accepted
Sep 17, 4:57 PM ET
Size
9.0 KB